Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDL BioPharma, Inc.

Latest From PDL BioPharma, Inc.

Fresenius And Formycon Strike Stelara Settlement For Europe And Canada

Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.

Deals Biosimilars

Bangers In MASH: How Rezdiffra's Rivals Stack Up

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

Clinical Trials Liver & Hepatic

Fresenius Divests Norwegian Plant To Prange

Fresenius Kabi has completed the divestment of a manufacturing plant in Halden, Norway, to Prange Group.

Manufacturing Deals

Fresenius Claims Edge With US Tocilizumab Biosimilar Approval

Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.

Biosimilars Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Eos Biotechnology, Inc.
    • LENSAR, Inc.
    • Noden Pharma DAC
    • Noden USA
    • Protein Design Labs, Inc.